RECRUITING

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.

Official Title

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes

Quick Facts

Study Start:2022-06-17
Study Completion:2027-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04791371

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Sedentary (defined as less than 1 hour per week of physical activity)
  2. * BMI: 25-40
  3. * Men and women with and without type 2 diabetes
  1. * Documented cardiovascular disease
  2. * Uncontrolled hypertension: disease systolic blood pressure (SBP) \> 150, diastolic blood pressure (DBP)\> 110
  3. * Obstructive pulmonary disease or asthma
  4. * Peripheral neuropathy
  5. * Physical impairment that would limit exercise ability
  6. * Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD)
  7. * Current or past smoking within the last 1 years
  8. * Current tobacco use
  9. * Anemia
  10. * Control HbA1c \> 5.7, T2DM HbA1c \> 9
  11. * Pregnant, nursing or hormonal therapy (other than contraceptives)
  12. * Peri or post-menopausal women
  13. * Type 1 diabetes
  14. * Hepatic or renal disease.

Contacts and Locations

Study Contact

Benjamin Juckett, MS
CONTACT
303-724-1338
benjamin.juckett@cuanschutz.edu

Study Locations (Sites)

University of Colorado
Aurora, Colorado, 80045
United States
University of Virginia
Charlottesville, Virginia, 22908
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-17
Study Completion Date2027-12-01

Study Record Updates

Study Start Date2022-06-17
Study Completion Date2027-12-01

Terms related to this study

Additional Relevant MeSH Terms

  • Type 2 Diabetes
  • Overweight and Obesity